Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
84 hedge funds and large institutions have $64.1M invested in Jounce Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 21 closing their positions.
1,260% more call options, than puts
Call options by funds: $136K | Put options by funds: $10K
64% more capital invested
Capital invested by funds: $39M → $64.1M (+$25.1M)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 85 → 84 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.57M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$3.92M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.57M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.35M |
| 5 |
ACM
Ardent Capital Management
Cincinnati,
Ohio
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$5.67M |
| 2 |
CAC
Cowen and Company
New York
|
-$4.05M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.01M |
| 4 |
Morgan Stanley
New York
|
-$1.91M |
| 5 |
Millennium Management
New York
|
-$1.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$5K | -4,882 | Closed |
|
102
Allspring Global Investments
Charlotte,
North Carolina
| – | -$835 | -753 | Closed |
|
103
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -750 | Closed |
|
104
Citigroup
New York
| – | -$472 | -425 | Closed |
|
|
CS
105
Credit Suisse
Zurich,
Switzerland
| – | -$2 | -2 | Closed |
|
JNCE Hedge Fund Activity: Q1 2023 in Review
84 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2023, worth a combined $64.1M — up 64% from $39M a quarter earlier.
Fund positioning in JNCE was balanced in Q1 2023: 21 funds opened new positions, 21 closed out, 21 added to existing stakes and 20 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $6.57M. The largest seller was RTW Investments, exiting entirely with an estimated $5.67M sold.
- 84 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2023, down from 85 in Q4 2022.
- Funds reported $64.1M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2023, up 64% quarter-over-quarter.
- 21 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2023 and 21 closed out, a net change of 0 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2023 was Tang Capital Management, an estimated $6.57M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2023 was RTW Investments, an estimated $5.67M sold.
Based on aggregated 13F filings for Q1 2023.